Human Immunodeficiency Virus (HIV1) Infection Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The human immunodeficiency virus (HIV1) infection market was valued at USD 20.64 Billion in 2025. It is poised to grow at a CAGR of 5.20% during the forecast period of 2026-2035, and reach USD 34.27 Billion by 2035. The market growth is driven by the rising global prevalence of human immunodeficiency virus infection, increasing awareness programs, expanded antiretroviral therapy access, and continuous advancements in long-acting and combination treatment options.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Human Immunodeficiency Virus (HIV1) Infection Market

United States: The Human Immunodeficiency Virus (HIV1) Infection Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.

Iran: Iran's domestic Human Immunodeficiency Virus (HIV1) Infection sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.

Israel: Israel's Human Immunodeficiency Virus (HIV1) Infection sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.

Key Takeaways

Government

• Relevant consumer protection agencies should monitor retail pricing for evidence of disproportionate margin-taking on top of genuine supply cost increases, ensuring that conflict-related cost inflation is not being amplified by opportunistic pricing behavior.
• Governments should consider targeted consumer support measures for lower-income households most exposed to rising fuel and food costs, preventing conflict-driven inflation from creating acute hardship among economically vulnerable populations.
• Trade authorities should work with the human immunodeficiency virus (hiv1) infection industry to identify import diversification opportunities that reduce dependence on Gulf-disrupted supply chains, stabilizing product availability and moderating consumer price inflation.

Market

• U.S. consumer inflation projected at 4.2% for 2026, gasoline above USD 4 per gallon, and global food price increases from fertilizer and logistics inflation are creating the most challenging consumer spending environment since 2022.
• Premium and essential categories within the human immunodeficiency virus (hiv1) infection market show different demand trajectories: premium segments serving ultra-high-net-worth consumers remain resilient, while mass-market discretionary segments face meaningful softening.
• Supply chain cost increases from 30% higher freight, 15-20% packaging inflation, and rising input material costs are compressing retailer and brand margins, creating pressure for pricing adjustments that may further moderate volume demand.

Procurement

• Consumer goods procurement teams should review packaging material sourcing, building 60-90 day buffer inventory of petroleum-derived packaging materials before further feedstock cost increases from the Gulf supply shock are transmitted into manufacturing costs.
• Logistics procurement managers should lock in freight contracts at current rates before further diesel cost increases are passed through by carriers, and evaluate route optimization strategies that reduce fuel cost exposure.
• Retail and brand buyers should update 2026 cost models to incorporate 30% higher freight costs, 15-20% packaging material inflation, and rising input material prices, ensuring that margin targets and pricing strategies reflect the new cost environment.

Key Market Trends and Insights

• By drug class, integrase strand transfer inhibitors are expected to dominate the drug class segment, accounting for approximately 38% of the market, driven by superior efficacy, safety profile, and widespread adoption in first-line HIV treatment regimens globally.
• By distribution channel, hospital pharmacies are projected to hold the largest share at around 52%, supported by centralized treatment distribution, higher patient footfall, and strong institutional access to antiretroviral therapies.
• Based on region, the United States is anticipated to lead the market with nearly 41% share, attributed to high treatment coverage, advanced healthcare infrastructure, and strong presence of key pharmaceutical players.

Market Size and Forecast

• Market Size (2025): USD 20.64 Billion
• Projected Market Size (2035): USD 34.27 Billion
• CAGR (2026-2035): 5.20%

Human Immunodeficiency Virus (HIV1) Infection Market Overview

The market is evolving steadily, driven by rising disease awareness, expanded screening programs, and improved access to antiretroviral therapy. Advances in long-acting injectables, combination regimens, and preventive strategies such as PrEP are reshaping treatment paradigms. Key players are focusing on pipeline innovation and global access initiatives. Emerging markets and government-led programs continue to support growth, while ongoing research aims to improve long-term disease management and functional cure strategies. The market reached a value of approximately USD 20.64 Billion in 2025.

Human Immunodeficiency Virus (HIV1) Infection Market Growth Drivers

Innovation and Long-Acting Therapies Driving the Market Development

Increasing R&D investments and continuous innovation in drug delivery systems are key drivers supporting market growth. For instance, in April 2026, The Global Fund expanded access to Gilead’s long-acting HIV drug lenacapavir, targeting millions globally. This development strengthens antiretroviral therapy access, improving adherence, expanding prevention coverage, and accelerating overall market growth during the forecast period.

Human Immunodeficiency Virus (HIV1) Infection Market Trends

Key trends shaping the market include rising adoption of long-acting therapies, expanding preventive strategies, increasing global awareness programs, and continuous innovation in HIV treatment technologies.

Regulatory Approvals and Prevention Expansion Accelerating the Market Landscape

Growing regulatory support and expansion of preventive strategies are accelerating market development. For instance, in June 2025, the World Health Organization acknowledged FDA approval of long-acting lenacapavir for HIV prevention, offering twice-yearly protection. This advancement reinforces HIV treatment programs, enhancing prevention adoption, improving patient compliance, and supporting long-term market development globally.

Human Immunodeficiency Virus (HIV1) Infection Market Segmentation

Market Breakup by Drug Class

• Nucleotide Reverse Transcriptase Inhibitor (NRTIs)
• Protease Inhibitors
• Integrase Strand Transfer Inhibitors (INSTIs)
• Entry and Fusion Inhibitors
• CCR5 Co-receptor Antagonists
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Others

Market Breakup by Drug Type

• Branded Drugs
• Generic Drugs

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channels

Market Breakup by End User

• Hospitals and Clinics
• Homecare Settings
• Others

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• India
• Japan

Human Immunodeficiency Virus (HIV1) Infection Market Share

Hospital Pharmacies Likely to Lead the Market Segment by Distribution Channel

Hospital pharmacies accounted for the largest share of the market in the historical period, contributing nearly 52%. This dominance is supported by centralized drug procurement systems, consistent patient inflow, and structured treatment protocols. The role of antiretroviral therapy access remains critical in ensuring treatment continuity, adherence monitoring, and optimized patient outcomes across institutional healthcare settings globally.

Human Immunodeficiency Virus (HIV1) Infection Market Analysis by Region

The United States led the market during the historical period, accounting for approximately 41% of the total share. This leadership is driven by advanced healthcare infrastructure, strong reimbursement frameworks, and extensive screening programs. The growing emphasis on HIV treatment programs further supports early diagnosis, improved patient management, and sustained demand for innovative therapeutic interventions nationwide.

Leading Players in the Human Immunodeficiency Virus (HIV1) Infection Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Gilead Sciences, Inc.

Founded in 1987 and headquartered in Foster City, California, Gilead Sciences is a leading biopharmaceutical company specializing in antiviral therapies. It dominates the HIV market with a strong portfolio of antiretroviral drugs. The company continues to advance HIV drug development through long-acting therapies and prevention strategies.

ViiV Healthcare Limited

Founded in 2009 and headquartered in London, United Kingdom, ViiV Healthcare is a global HIV-focused company specializing in antiretroviral therapies and long-acting injectable treatments. Its HIV-1 therapeutics portfolio includes cabotegravir-based regimens and combination therapies. In 2025, ViiV expanded long-acting injectable access across global treatment programs.

Merck & Co., Inc.

Established in 1891 and headquartered in Rahway, New Jersey, United States, Merck & Co. is a leading pharmaceutical company with strong antiviral research capabilities. Its antiretroviral pipeline includes investigational HIV integrase inhibitors and combination therapies. In 2026, Merck advanced clinical studies for next-generation HIV prevention options.

Bristol-Myers Squibb Company

Founded in 1887 and headquartered in New York, United States, Bristol-Myers Squibb focuses on innovative medicines, including virology treatments. Its HIV treatment portfolio historically included protease inhibitors and combination antiretroviral regimens. In 2025, BMS continued lifecycle management efforts in its virology collaborations and research programs.

Other key players in the market are AbbVie Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Janssen Pharmaceuticals, Inc., Viatris Inc., and Boehringer Ingelheim International GmbH.

Key Questions Answered in the Human Immunodeficiency Virus (HIV1) Infection Market Report

• What was the human immunodeficiency virus (HIV1) infection market value in 2025?
• What is the human immunodeficiency virus (HIV1) infection market forecast outlook for 2026-2035?
• What major factors aid the demand for human immunodeficiency virus (HIV1) infection market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major human immunodeficiency virus (HIV1) infection market trends?
• Which drug class is expected to dominate the market segment?
• Which drug type is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the human immunodeficiency virus (HIV1) infection market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?